cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1562Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMОт комбинированной терапии к фиксированной комбинацииFrom combined therapy to fixed-dose combinationsКолосИ. П.KolosI. P.docsn173@yandex.ruБойцовС. А.BoytsovS. A.docsn173@yandex.ruФГУ “Российский кардиологический научно-производственный комплекс Росмедтехнологии”, г. МоскваRussian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow200820082008748994Copyright © Колос И.П., Бойцов С.А., 20082008Колос И.П., Бойцов С.А.Kolos I.P., Boytsov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1562

Due to low effectiveness of arterial hypertension (AH) monotherapy, recent debates have concentrated on evidence-based effectiveness and safety of combined AH therapy. To improve treatment compliance, reduce treatment costs, and increase therapy effectiveness, fixed-dose combined antihypertensive therapy is used more and more actively. One of such fixed-dose combinations, with proved effectiveness and safety, is Tarka medication, including trandolapril and verapamil. The article reviews the literature data demonstrating fixed-dose trandolapril+verapamil combination effects on blood pressure level and target organ damage in AH, renal failure, diabetes mellitus, and coronary heart disease.

 

фиксированная комбинацияартериальная гипертониятрандолаприлверапамилfixed-dose combinationarterial hypertensiontrandolaprilverapamilReferencesWaeber В., Burnier M., Brunner H.R. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973-85.Waeber В., Burnier M., Brunner H.R. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973-85.Bangalore S., Kamalakkannan G., Panjrath G., Messerli F.H. Fixed-dose combination improves medication compliance: a meta-analysis. J Clin Hypertens.2006; 8 (Suppl A): A72 (abstract).Bangalore S., Kamalakkannan G., Panjrath G., Messerli F.H. Fixed-dose combination improves medication compliance: a meta-analysis. J Clin Hypertens.2006; 8 (Suppl A): A72 (abstract).Dahlof B., Sever P.S., Poulter N..R, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as equired versus atenolol adding bendofiumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Dahlof B., Sever P.S., Poulter N..R, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as equired versus atenolol adding bendofiumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Jamerson K.A., Bakris G.L., Wun C.C., et al. Rationale and design of the avoiding cardiovascular vents through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17: 793-801.Jamerson K.A., Bakris G.L., Wun C.C., et al. Rationale and design of the avoiding cardiovascular vents through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17: 793-801.Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living with Systolic Hypertension, the Early Termination of the ACCOMPLISH Trial for Efficacy. Presented by Dr. Kenneth Jamerson at the SCAI-ACC i2 Summit/American College of Cardiology Annual Scientific Session, Chicago, IL, March/April 2008.Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living with Systolic Hypertension, the Early Termination of the ACCOMPLISH Trial for Efficacy. Presented by Dr. Kenneth Jamerson at the SCAI-ACC i2 Summit/American College of Cardiology Annual Scientific Session, Chicago, IL, March/April 2008.Сидоренко Б.А., Преображенский Д.В. Трандолаприл (гоп-тен) -ингибитор АПФ третьего поколения. Клин фармак тер 1998; 7(3): 68-75.Сидоренко Б.А., Преображенский Д.В. Трандолаприл (гоп-тен) -ингибитор АПФ третьего поколения. Клин фармак тер 1998; 7(3): 68-75.Мартынов А.И., Аветян H.F., Еороховская F.H. и др. Антигипертензивные и органопротективные эффекты комбинированной терапии ингибиторов ангиотензин-пре-вращающего фермента и антагонистом кальция. Cons Med 2006; 8(11): 9-13.Мартынов А.И., Аветян H.F., Еороховская F.H. и др. Антигипертензивные и органопротективные эффекты комбинированной терапии ингибиторов ангиотензин-пре-вращающего фермента и антагонистом кальция. Cons Med 2006; 8(11): 9-13.Ruggenenti P., Fassi A., Ilieva А.Р., et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.Ruggenenti P., Fassi A., Ilieva А.Р., et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.Bakris G., Molitch M., Hewkin A., et al; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29(12): 2592-7.Bakris G., Molitch M., Hewkin A., et al; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29(12): 2592-7.Petrie J.R., Morris A.D., Ueda S., et al. Trandolapril does not affect insulin sensitivity in patients with essential hypertension and impaired glucose Tolerance/NIDDM. J Hypertens 1997; 15(12): 1542.Petrie J.R., Morris A.D., Ueda S., et al. Trandolapril does not affect insulin sensitivity in patients with essential hypertension and impaired glucose Tolerance/NIDDM. J Hypertens 1997; 15(12): 1542.Libreti A., Catalano M., SLIP study group. Lipid profile during antihypertensive treatment. Drugs 1993; 46 (Suppl. 2): 16-23.Libreti A., Catalano M., SLIP study group. Lipid profile during antihypertensive treatment. Drugs 1993; 46 (Suppl. 2): 16-23.Rett K, Wicklmayr M. Unchanged insulin sensitivity with verapamil SR plus trandolapril in lowdose combination in NIDDM with Stage I hypertension. Diabetologia 1997; 40 (Suppl. 1): A367.Rett K, Wicklmayr M. Unchanged insulin sensitivity with verapamil SR plus trandolapril in lowdose combination in NIDDM with Stage I hypertension. Diabetologia 1997; 40 (Suppl. 1): A367.Femδndez R., Puig J.G., Rodrнguez-Рйrez J.C, et al.; TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15:849-56.Femδndez R., Puig J.G., Rodrнguez-Рйrez J.C, et al.; TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15:849-56.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.Преображенский Д.В., Сидоренко Б.А., Скорик А.В., Некрасова Н.И. Преимущества комбинированной терапии артериальной гипертензии: новая фиксированная комбинация ингибитора ангиотензинпревращающего фермента и антагониста кальция. Cons Med 2007; 9(11): 38-45.Преображенский Д.В., Сидоренко Б.А., Скорик А.В., Некрасова Н.И. Преимущества комбинированной терапии артериальной гипертензии: новая фиксированная комбинация ингибитора ангиотензинпревращающего фермента и антагониста кальция. Cons Med 2007; 9(11): 38-45.Steven A. Atlas, The Renin-Angiotensin Aldosteron System: pathophysiological role and pharmacologic inhibitions. JMCP 2007; 13.Steven A. Atlas, The Renin-Angiotensin Aldosteron System: pathophysiological role and pharmacologic inhibitions. JMCP 2007; 13.Zannad F., Matzinger A., Larche J. Trough/peak ratios of once daily angiotensin coverting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-43.Zannad F., Matzinger A., Larche J. Trough/peak ratios of once daily angiotensin coverting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-43.

The authors declare that there are no conflicts of interest present.